IMI (Inverness Medical Innovations) completes buy of Apogent's Applied Biotech:
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations (IMI) has completed its acquisition of San Diego, California-based Applied Biotech, the rapid diagnostic test manufacturing subsidiary of Apogent Technologies. The deal releases Apogent from any further patent infringement claims by IMI relating to products sold by Apogent before the acquisition closed. Apogent decided to sell the unit because of its exposure to IMI's patent protection action in the fields of rapid pregnancy, drugs of abuse and infection testing (see Clinica No 1069, p 15).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.